4 unknown, 3 completed. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Unknown 4, Completed 3 |
| Phase 2 | 1 | Unknown 1 |
Follow Tehran Heart Center: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Empagliflozin to Prevent Post-Operative Atrial Fibrillation Empagliflozin 10 MG, Placebo - Post-operative Atrial Fibrillation, CABG | Phase 3 | Unknown | Rajaie Cardiovascular Medical and Research Center | 492 | 2023-11-07 | 2023-11-22 |
| Midodrine and Fludrocortisone for Vasovagal Syncope Midodrine Hydrochloride Tablets, Fludrocortisone Acetate Tablets, Lifestyle modification - Syncope, Vasovagal | Phase 3 | Unknown | Tehran Heart Center | 1375 | 2020-11-19 | 2021-04-19 |
| Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI Rivaroxaban 15 MG, Warfarin - Left Ventricular Thrombus, ST Segment Elevation Myocardial Infarction | Phase 3 | Completed | Rajaie Cardiovascular Medical and Research Center | 50 | 2020-07-30 | 2023-04-07 |
| Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19 intermediate dose Enoxaparin/ unfractionated heparin, standard prophylactic dose Enoxaparin/ unfractionated heparin, Atorvastatin 20mg - Covid19 | Phase 3 | Completed | Rajaie Cardiovascular Medical and Research Center | 600 | 2020-07-30 | 2021-08-17 |
| N-Acetyl Cystein and Contrast Nephropathy Oral N-Acetyl Cystein, IV N-Acetyl Cystein, Placebo group - Chronic Kidney Disease Stage 2, Radiographic Contrast Agent Nephropathy | Phase 3 | Unknown | Imam Khomeini Hospital | 549 | 2013-03-01 | 2013-03-28 |
| Nephrogenic Systemic Fibrosis With Gadollinum gadollinum - Nephrogenic Systemic Fibrosis, Renal Failure | Phase 2 / Phase 3 | Unknown | Imam Khomeini Hospital | 200 | 2008-07-01 | 2012-06-22 |
| Effect of Sodium Bicarbonate Solution in Decreasing the Incidence of Contrast Induced Nephropathy (CIN) Sodium Bicarbonate plus normal saline 0.9%, normal saline 0.9% - Contrast Induced Nephropathy | Phase 3 | Completed | Tehran University of Medical Sciences | 265 | 2007-08-01 | 2008-09-05 |
Atrial Fibrillation (1) · COVID-19 (1) · Kidney Failure, Chronic (1) · Nephrogenic Fibrosing Dermopathy (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1) · ST Elevation Myocardial Infarction (1) · Syncope (1) · Syncope, Vasovagal (1) · Thrombosis (1)
Atorvastatin (1) · Heparin (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Midodrine (1) · Rivaroxaban (1) · Saline Solution (1) · Sodium Bicarbonate (1) · Warfarin (1) · empagliflozin (1) · fludrocortisone acetate (1)
Iran (7)
Mohammad R Khatami, MD (2) · Ahmad Iaminisharif, M.D. (1) · Akbar Fotuhi, M.D. (1) · Ali Kazemi-Saeid, MD (1) · Ali Vasheghani-Farahani, M.D. (1) · Alireza Amirzadegan, M.D. (1) · Amir Hossein Razavi, M.D. (1) · Arash Jalali, PhD (1) · Arya Aminorroaya, MD, MPH (1) · Behnood Bikdeli, MD, MS (1) · Ebrahim Kassaian, M.D. (1) · Ebrahin Kassaian, MD (1) · Farah Aiatollahzade Esfehani, BSc,RN (1) · Gelareh Sadigh, M.D. (1) · Gholamreza Davoodi, M.D. (1)
PMID 32992075, PMID 33734299, PMID 34996756, PMID 35165110, PMID 35244208, PMID 36944357, PMID 39773831